<DOC>
	<DOCNO>NCT01737294</DOCNO>
	<brief_summary>This non-interventional study evaluate efficacy , tolerability , health relate quality life use health resource associate QUTENZA treatment QUTENZA use standard clinical practice . The patient 's primary diagnosis peripheral neuropathic pain ( PNP ) classify subtypes : post-herpetic neuralgia ( PHN ) ; HIV-associated neuropathy ( HIV-AN ) ; neuropathic back pain ; cancer-related neuropathic pain ; post-operative &amp; post-traumatic neuropathic pain ; 'other ' neuropathy .</brief_summary>
	<brief_title>Observation Use QUTENZAâ„¢ Standard Clinical Practice</brief_title>
	<detailed_description>A detailed medical history take , particular emphasis primary PNP diagnosis . In addition current neuropathic pain medication , previous therapy ( pharmacological surgical ) PNP point primary diagnosis document . QUTENZA treatment may repeat every 90 day , line Summary Product Characteristics document ( SPC ) determine persistence return pain . Patients require treatment 365 day longer may re-enter treatment cycle treat physician decides retreat QUTENZA course standard clinical management . The duration participation patient least 12 month follow first QUTENZA treatment . Short questionnaire complete investigator whilst contact patient ( either person telephone ) follow time point : 1 ) Screening prior first QUTENZA treatment ; 2 ) QUTENZA treatment visit ; 3 ) 2 week , 8 week follow first QUTENZA treatment 4 ) 12 week follow QUTENZA treatment ; 5 ) additional contact patient outside protocol schedule . For patient return retreatment QUTENZA within 6 month , 9 month , 1 year previous QUTENZA treatment follow-up questionnaire complete . End study ( EoS ) define one year last patient enrol receives first QUTENZA treatment .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>1 . The investigator decide treat patient QUTENZA part provision standard care treatment peripheral neuropathic pain nondiabetic adult either alone combination medicinal product pain 2 . The patient willing able comply protocol requirement duration study participation 1 . The neuropathic painful area locate face , hairline scalp , and/or proximity mucous membrane 2 . The patient history Type I Type II diabetes mellitus 3 . The patient diagnosis major psychiatric disorder evidence cognitive impairment include dementia , opinion investigator , may interfere patient 's ability complete study evaluation 4 . The patient receive prior treatment QUTENZA patch , include blind patch administer part clinical trial 5 . The patient hypersensitivity capsaicin ( i.e . chilli pepper overthecounter [ OTC ] capsaicin product ) , QUTENZA excipients adhesive , local anesthetic 6 . The patient participate clinical study receive investigational drug within 30 day prior Screening Visit 7 . The patient currently engage active substance abuse history chronic substance abuse within 1 year prior Screening Visit ; prior chronic substance abuse ( include alcoholism ) likely reoccur study period judge investigator 8 . The patient , opinion investigator , suitable participate NIS reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase IV</keyword>
	<keyword>Peripheral Neuropathic Pain</keyword>
	<keyword>QUTENZA</keyword>
</DOC>